Assessment of the course and burden of adverse drug reactions over time attributed to using TNFα-inhibitors in patients with inflammatory rheumatic diseases
Latest Information Update: 30 Jun 2022
At a glance
- Drugs Adalimumab (Primary) ; Certolizumab pegol (Primary) ; Etanercept (Primary) ; Golimumab (Primary) ; Infliximab (Primary)
- Indications Axial spondyloarthritis; Psoriatic arthritis; Rheumatoid arthritis
- Focus Adverse reactions
- 30 Jun 2022 New trial record
- 04 Jun 2022 Results presented at the 23rd Annual Congress of the European League Against Rheumatism